Option chain shows key data for Sonnet BioTherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sonnet BioTherapeutics.

Sonnet BioTherapeutics (NASDAQ:SONN) Stock, Option Chain

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Record High Gold Prices

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

CTKB

NOVA

PACS

SONN

TMCI

ZCAR

Gold Down Over 2%; CVS Health Shares Jump After Q3 Results

5 Things Moving As Trump Trade Fever Sweeps Wall Street Amid Election Night Drama

Intraday Update

FOXO

Dow Jumps Over 1,200 Points; Donald Trump Wins White House

Wall-Street-dall

Price Target

Analyst Ratings

AMIX

EVOK

HCTI

UPXI

Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

Health Care

Press Releases

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Management

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

General

Sonnet Announces Release of Corporate Update Video

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

MBRX

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Palisade Bio

Plus Therapeutics

Palatin Techs

Sunshine Biopharma

SILO Pharma

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Chardan Capital

EF Hutton

Ladenburg Thalmann

Comments

Sonnet BioTherapeutics

Sonnet BioTherapeutics (SONN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell